ReviewCurrent treatment options in allergy2020
A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.
Review in Current treatment options in allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.Annals of oncology : official journal of the European Society for Medical Oncology · 2020Guideline
- A one health perspective on the intestinal microbiome's role in COVID-19 outcomes and recovery.Frontiers in cellular and infection microbiology · 2026Review
- Unveiling the Disparities in the Field of Precision Medicine: A Perspective.Health science reports · 2025Article
- Inflammatory Markers Predict Blood Neurofilament Light Chain Levels in Acute COVID-19 Patients.International journal of molecular sciences · 2024Article
- Common variants of pro-inflammatory gene IL1B and interactions with PPP1R13L and POLR1G in relation to lung cancer among Northeast Chinese.Scientific reports · 2023Article
- Crowdsourcing temporal transcriptomic coronavirus host infection data: Resources, guide, and novel insights.Biology methods & protocols · 2023Article
- COVID-19 diagnostics: Molecular biology to nanomaterials.Clinica chimica acta; international journal of clinical chemistry · 2023Review
- Longwise Cluster Analysis for the Prediction of COVID-19 Severity within 72 h of Admission: COVID-DATA-SAVE-LIFES Cohort.Journal of clinical medicine · 2022Article
- COVID-19 challenges: From SARS-CoV-2 infection to effective point-of-care diagnosis by electrochemical biosensing platforms.Biochemical engineering journal · 2021Review
- In vitro induction of interleukin-8 by SARS-CoV-2 Spike protein is inhibited in bronchial epithelial IB3-1 cells by a miR-93-5p agomiR.International immunopharmacology · 2021Article
- Identifying molecular insight of synergistic complexities for SARS-CoV-2 infection with pre-existing type 2 diabetes.Computers in biology and medicine · 2021Article
- Article
- Development of a novel risk score for the prediction of critical illness amongst COVID-19 patients.International journal of clinical practice · 2021Article
- An overview of vaccine development for COVID-19.Therapeutic delivery · 2021Review
- The find of COVID-19 vaccine: Challenges and opportunities.Journal of infection and public health · 2021Review
- How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn.Life (Basel, Switzerland) · 2021Review
- Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health.Journal of personalized medicine · 2021Review
- Lessons learned from COVID-19 pandemic in Italy - A commentary.Bosnian journal of basic medical sciences · 2021Article
- Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Review
- Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients.Experimental eye research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPrecision medicine (PM) represents a new paradigm in disease diagnosis, prevention, and treatment. To apply PM premises in an emerging coronavirus pandemic acquires potentially greater relevance in order to allow the selection of specific preventive measures as well as biomarkers that will be useful in disease management. RECENT
findingsThe identification of the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the responsible for the coronavirus disease 2019 (COVID-19) pandemic had led to a plethora of strategies to contain viral dissemination, affecting life styles and personal behaviors. Viral genomic sequencing has shown that SARS-CoV-2 spike protein utilizes angiotensin-converting enzyme 2 (ACE2) found on ciliated epithelial cells of the human lungs as its specific receptor. Neutralizing antibodies to the receptor-binding domain of the spike protein were detected in patients recovered from COVID-19; however, both T cells and NK cells were reduced in severe cases. Excessive and uncontrolled releases of pro-inflammatory cytokines such as IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor (TNFα) were increased in severe patients. These cytokines might be useful biomarkers of disease worsening and potential targets for new biological therapies currently under investigation. SUMMARY: Present knowledge and recent developments in PM approach to COVID-19 disease prevention, evaluation, and management are pointed out. Better understanding of pathogenic pathways together with an accurate phenotype classification of patients presented with SARS-CoV-2 infection and symptoms might contribute to a more accurate definition of biomarkers and other diagnostic tools, which may lead to more precise mitigation strategies, personalized pharmacologic options, as well as new biological therapy developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.